Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha(®)), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fca.15.89 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of dyslipidemia management in Turkey using a Delphi panel.
Sci Rep
December 2024
Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
This study evaluated the management of dyslipidemia in Turkey with the goal of understanding current diagnosis and treatment patterns, as well as identifying unmet needs in achieving effective low-density lipoprotein cholesterol (LDL-C) targets. Using a Delphi panel consisting of nine expert cardiologists, the study reveals key gaps in dyslipidemia management, particularly in the underutilization of combination therapies, such as statins and PCSK9 inhibitors, which are crucial for achieving LDL-C targets in high-risk patients. The findings indicate that while many patients with very high cardiovascular risk are diagnosed, a significant proportion do not receive optimal treatment to reach LDL-C levels recommended by European guidelines.
View Article and Find Full Text PDFEffects of specific symbiotic supplements on anthropometric measurements, glycaemic control, and lipid profiles among individuals with type 2 diabetes mellitus in two teaching hospitals in Baghdad/Iraq: a double-blinded, randomised placebo-controlled trial.
BMC Nutr
December 2024
Epsom General Hospital, Epsom and St Helier University Hospitals NHS, Epsom, United Kingdom.
Background: Experimental and clinical studies have suggested that symbiotics might effectively manage type 2 diabetes mellitus (T2DM) by modulating the intestinal microbiota. However, these studies' limited sources, small sample sizes, and varied study designs have led to inconsistent outcomes regarding glycaemic control. This study aimed to investigate the effects of symbiotics on the anthropometric measures, glycaemic control, and lipid profiles of patients with T2DM.
View Article and Find Full Text PDFSynthesis, spectroscopic, computational, molecular docking, antidiabetic(in vitro & in vivo) DNA and BSA interaction studies of ruthenium(II) carboxylate complexes.
Spectrochim Acta A Mol Biomol Spectrosc
December 2024
Department of Chemistry, COMSATS University, Abbottabad 22060, KPK, Pakistan.
The ruthenium compounds have been known to have the wide range of potential applications as anticancer, antibacterial and anti-diabetic etc. The ligand substitutions play a vital role in enhancing the pharmacological and biological activities. In the present study, three ruthenium-metal based complexes, designated as (I-III), were synthesized and characterized employing element analysis, FTIR and HNMR.
View Article and Find Full Text PDFA well-balanced vegan diet does not compromise daily mixed muscle protein synthesis rates when compared to an omnivorous diet in active older adults: a randomized controlled cross-over trial.
J Nutr
December 2024
Division of Human Nutrition and Health, Wageningen University, Wageningen, The Netherlands.
Background: Plant-based foods have reduced protein digestibility and frequently display unbalanced amino acid profiles. Plant-based foods are therefore considered inferior to animal-based foods in their anabolic potential. No study has assessed the anabolic potential of a vegan diet that provides a large variety of plant-based protein sources in older adults.
View Article and Find Full Text PDFThe intEgrated multidiscipliNary pathway for large-scale maNagement of dyslipidemiA in high-risk patients (ENNA) project: Rationale and project design.
Am J Cardiol
December 2024
Università degli Studi di Enna "Kore", Enna, Italy; Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, Enna, Italy. Electronic address:
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally, significantly influenced by modifiable risk factors, particularly hypercholesterolemia. Despite the availability of effective lipid-lowering drugs, achieving the low-density lipoprotein cholesterol (LDL-C) target levels remains a significant challenge in clinical practice, contributing to persistent high rates of cardiovascular events. The intEgrated multidiscipliNary pathway for large-scale maNagement of dyslipidemiA in high-risk patients (ENNA) Project was designed to address the alarming rates of suboptimal lipid management among high and very-high risk patients in the Province of Enna, Sicily.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!